Although these drugs are primarily indicated for diabetes, several studies have examined their use and found that SGLT2 inhibitors may reduce the risk of cardiovascular outcomes in patients with T2DM and CKD, with no evidence of additional safety concerns. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.